Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105174 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL142968 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL29069175 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL29039966 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL29039969 | 1.00 | PPM1D (0.36) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL15519970 | 0.90 | PPM1D (0.32) | PPM1DNR1H2USP2SMN1; SMN2 | |
| SCHEMBL31104974 | 0.89 | PPM1D (0.34) | PPM1DUSP2SMN1; SMN2 | |
| SCHEMBL1269216 | 0.88 | PPM1D (0.31) | PPM1D | |
| SCHEMBL1269218 | 0.88 | PPM1D (0.31) | PPM1D | |
| SCHEMBL14348107 | 0.88 | PPM1D (0.31) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496314-B | Preparation method of (2S, 4S) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-116496314-A | Preparation method of (2S, 4S) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-116496314-B | Preparation method of (2S, 4S) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-116496314-B | Preparation method of (2S, 4S) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-116496314-B | Preparation method of (2S, 4S) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-116496314-A | Preparation method of (2S, 4S) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116496314-A | Preparation method of (2S, 4S) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116496314-A | Preparation method of (2S, 4S) -1- (tert-butyloxycarbonyl) -4- (tert-butyldimethylsilyloxy) -2-methylpyrrolidine-2-carboxylic acid | 南京优氟医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | PPM1D 40/4885NR1H2 2154/4885USP2 703/4885 |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | PPM1D 40/4885NR1H2 2154/4885USP2 703/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | PPM1D 528/4885NR1H2 2872/4885USP2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.